Senior Director, Portfolio Integration Lead - Hematology

Senior Director, Portfolio Integration Lead - Hematology

Cancer is unrelenting, but so are we. At GSK, we are committed to transforming outcomes for people with cancer through innovative science, bold ambition, and strong partnerships across the healthcare ecosystem. We focus our science where it can matter most - advancing care in cancers with high unmet need, grounded in a deep understanding of disease biology and deliberate scientific choices that connect discovery to meaningful impact in the real world.

The Portfolio Integration Lead (PIL) is a senior role in Oncology Clinical Development, responsible for shaping the advancement of multiple oncology programmes from our portfolio with a focus on particular cancers. Working closely with both the VP and Clinical Development Leads (CDLs) and cross-functional teams across GSK, this role ensures scientific alignment, portfolio coherence, and development excellence across assets. This is a senior individual contributor position that operates across the full breadth of an Oncology portfolio rather than within a single programme, enabling cross-asset integration and strategic alignment across development activities.

The PIL applies a disease-level clinical and scientific lens across the portfolio, integrating disease biology, biomarker strategy, and emerging clinical approaches to define what is scientifically feasible and inform development pathways across programmes. This includes bringing clinical context to novel biomarker strategies and trial designs, particularly for early-stage and mechanistically novel assets and across programmes with similar indications.

The position is open to candidates from either a medical or non-medical background based on the expertise required to be successful operating at the intersection of oncology disease strategy, clinical development, and portfolio leadership.

• Provide senior scientific partnership to CDLs, particularly in areas such as disease biology, biomarker strategy, and novel treatment combinations development.
• Ensure consistent cross-programme ways of working to improve development efficiency and execution.
• Drive cross-programme portfolio working groups and ensure business level alignment
• Drive and support clinical trial innovation based on evolving oncology treatment landscape, government regulations, basic/translational science, and emerging technologies (such as AI-enabled tools).
• Strengthen the scientific and strategic positioning of a pan-asset portfolio across multiple clinical and pre-clinical assets.
• Drive initiatives that advance data and technology strategies supporting development decision-making.
• Shape engagement with external experts and governance bodies including advisory boards where relevant.

Portfolio Strategy & Cross-Program Integration

• Shape the advancement of multiple development programs within the oncology portfolio by providing scientific insights across assets, ensuring that agreed disease strategy is implemented consistently across programs.
• Prepare detailed strategic analyses and portfolio recommendations on behalf of the Disease Area Vice President, enabling effective decision-making at senior leadership and governance levels.
• Ensure alignment and coordination across Clinical Matrix Teams (CMTs) and relevant cross-functional stakeholders in Research & Development (R&D), Global Medical Affairs (GMA) and Global Product Strategy (GPS).
• Drive disease-level strategic discussions and portfolio planning, bringing a pan-asset perspective to governance discussions and portfolio prioritization.
• Serve as a subject matter expert supporting global health authority interactions, regulatory submissions and key development milestones across multiple assets.

Partnership with Clinical Development Leads

• Serve as a scientific thought partner to CDLs across multiple asset programs, shaping key aspects of clinical development strategy for a given tumour types, including:
• disease biology and translational science
• biomarker and precision medicine approaches
• combination strategies
• emerging clinical development opportunities

Clinical Development Excellence

• Establish and champion consistent ways of working across programs to improve efficiency and development quality.
• Drive innovation in clinical development approaches for a given disease area, including trial design, novel endpoints, and emerging technologies such as AI-enabled analytics where appropriate.

External Scientific Engagement

• Maintain a deep understanding of the evolving tumour disease landscape, standards of care, and emerging science.
• Shape engagement with external experts through advisory boards.
• Synthesize portfolio-level external insights to inform and strengthen development strategy across multiple programs.

Data & Innovation Strategy

• Drive initiatives that strengthen the application of data, technology, and analytics in clinical development decision-making for a given tumour type.
• Champion innovative approaches to clinical trials and…